β-Blockers in the Treatment of Hypertension: Are There Clinically Relevant Differences?

References

• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Rosamond W, Flegal K, Furie K, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–e146
   PubMed Web of Science ®Google Scholar
• . Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223
   PubMed Web of Science ®Google Scholar
• . Burt VL, Whelton P, Roccella EJ, . Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–313
   PubMed Web of Science ®Google Scholar
• . Williams GH. Approach to the patient with hypertension. In: Braunwald E, Kasper DL, Hauser SL, eds. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill; 2001:211–213
   Google Scholar
• . Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 pt 2):724–728
   PubMed Web of Science ®Google Scholar
• . Guyton AC, Hall JE. Nervous regulation of the circulation and rapid control of arterial pressure. Textbook of Medical Physiology. Philadelphia, PA: W.B. Saunders Co; 2000:184–194
   Google Scholar
• . Guyton AC, Hall JE. Dominant role of the kidney in long-term regulation of arterial pressure and in hypertension: the integrated system for pressure control. Textbook of Medical Physiology. Philadelphia, PA: W.B. Saunders, Co; 2000:195–209
   Google Scholar
• . Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005;7(7): 409–416
   PubMedGoogle Scholar
• . Frishman WH. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens. 2007;9:19–27
   PubMedGoogle Scholar
• . Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, eds. Goodman and Oilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001
   Google Scholar
• . Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100(5):323–337
   PubMed Web of Science ®Google Scholar
• . Hofman A, Boomsma F, Schalekamp MA, Valkenburg HA. Raised blood pressure and plasma noradrenaline concentrations in teenagers and young adults selected from an open population. Br Med J. 1979;1(6177):1536–1538
   PubMedGoogle Scholar
• . Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31(1):68–72
   PubMedGoogle Scholar
• . Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43(4): 699–706
   PubMed Web of Science ®Google Scholar
• . Kaplan NM. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: W.B. Saunders Co; 1997
   Google Scholar
• . Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007;115(15):1999–2005
   PubMedGoogle Scholar
• . Strand AH, Gudmundsdottir H, Os I, . Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006;24(5):905–913
   PubMed Web of Science ®Google Scholar
• . Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 suppl 1):39–52
   PubMedGoogle Scholar
• . Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563–572
   PubMed Web of Science ®Google Scholar
• . Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737–1742
   PubMed Web of Science ®Google Scholar
• . Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545–1553
   PubMed Web of Science ®Google Scholar
• . Lopez-Sendon J, Swedberg K, McMurray J, ; Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004; 25(15): 1341–1362
   PubMed Web of Science ®Google Scholar
• . Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269–277
   PubMed Web of Science ®Google Scholar
• . Blumenfeld JD, Sealey JE, Mann SJ, . Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12(5):451–459
   PubMed Web of Science ®Google Scholar
• . Cambridge D, Whiting MV, Butterfield LJ, Allan G. The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs. Br J Pharmacol. 1992;106(2):342–347
   PubMedGoogle Scholar
• . Messerli FH, Grossman E. Beta-Blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(9A):7B–12B
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Fonseca V, Katholi RE, ; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–2236
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Bell DS, Fonseca V, ; GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120(7):610–615
   PubMedGoogle Scholar
• . Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12(4):212–221
   PubMedGoogle Scholar
• . Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67(8):1097–1107
   PubMed Web of Science ®Google Scholar
• . Kanto JH. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23(11):617–628
   PubMedGoogle Scholar
• . Novo S, Abrignani MG, Sapienza ND, . Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol. Int Angiol. 1992;11(2):137–141
   PubMedGoogle Scholar
• . Abernethy DR, Bartos P, Plachetka JR. Labetalol in the treatment of hypertension in elderly and younger patients. J Clin Pharmacol. 1987;27(11):902–906
   PubMedGoogle Scholar
• . Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens. 1985;1(1):56–69
   PubMedGoogle Scholar
• . VHA Pharmacy Benefits Management Services, Medical Advisory Panel. National PBM Drug Monograph Nebivolol (Bystolic®). pbm.va.gov/monograph/Nebivolol.doc. 2008
   Google Scholar
• . Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92(3):344–348
   PubMed Web of Science ®Google Scholar
• . Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag. 2006;2(3):303–308
   PubMedGoogle Scholar
• . Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007;9(9):667–676
   PubMedGoogle Scholar
• . Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19(4):419–425
   PubMedGoogle Scholar
• . Kozlovski VI, Lomnicka M, Chlopicki S. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep. 2006;58( suppl):103–110
   PubMedGoogle Scholar
• . Weber K, Bohmeke T, van der Does R, Taylor SH. Hemodynamic differences between metoprolol and carvedilol in hypertensive patients. Am J Hypertens. 1998;11(5):614–617
   PubMedGoogle Scholar
• . Weber MA, Bakris GL, Tarka EA, Iyengar M, Fleck R, Sica DA. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8(12):840–849
   PubMedGoogle Scholar
• . Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL. Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006;98(7A):32L–38L
   PubMed Web of Science ®Google Scholar
• . Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother. 2006;7(18): 2533–2546
   PubMed Web of Science ®Google Scholar
• . ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997
   PubMed Web of Science ®Google Scholar
• . Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich). 2008;10 (1 suppl 1):4–12
   PubMedGoogle Scholar
• . Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427
   PubMed Web of Science ®Google Scholar